• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA strengthens management team with the appointment of Alain Deloof as head of the mRNA production lab

eTheRNA is on track to move the mRNA production unit from Jette to Niel in 2017 and to triple its capacity

Alain Deloof - Head of the mRNA production lab Brussels (Belgium), 4 August 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Alain Deloof (foto) as Production Lead , effective August 1, 2016.